Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma

• DOI: 10.1677/erc-08-0211
• Publication Date: 2009-05-24T00:24:17Z
• Authors: Wiebke Fenske; Hans-Ullrich Völker; Patrick Adam; Stefanie Hahner; Sarah Johanssen; Sebastian Wortmann; Melanie Schmidt; Michael Morcos; Hans-Konrad Mülle...; Bruno Allolio; Martin Fassnacht
• Keywords: GLUT3; Tissue microarray; Univariate analysis

Owing to the rarity of adrenocortical carcinoma (ACC) no prognostic markers have been established beyond stage and resection status. Accelerated glycolysis is a characteristic feature cancer cells in variety tumour entities key factors glucose metabolism like transporter 1 3 (GLUT1 -3), transketolase like-1 enzyme (TKTL1) pyruvate kinase type M2 (M2-PK) are overexpressed value. Therefore, we investigated role these ACC. Immunohistochemical analysis was performed on tissue microarrays paraffin-embedded samples from 167 ACCs, 15 adrenal adenomas 4 normal glands. Expression correlated with baseline parameters clinical outcome. GLUT1 -3 were expressed 33 17% ACC respectively, but none benign tumours or adrenals By contrast, TKTL1 M2-PK detectable all tissues vast majority ACCs. expression strongly associated prognosis univariate multivariate (P<0.01), whereas GLUT3, did not correlate Patients strong staining showed considerably higher overall mortality (hazard ratio (HR) 6.34 (95% confidence interval 3.10-12.90) compared patients staining. When analysing their early stages advanced disease separately, similar results obtained. HR for survival 5.31 (1.80-15.62) metastatic after radical disease-free 6.10 (2.16-16.94). In conclusion, highly promising stage-independent, marker